Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.
On 13 May 2011, orphan designation (EU/3/11/867) was granted by the European Commission to Fate Therapeutics LTD, United Kingdom, for allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute myeloid leukaemia.
EU/3/11/867: Public summary of opinion on orphan designation: Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute myeloid leukaemia (PDF/146.26 KB)
First published: 30/05/2011
Last updated: 30/08/2019
Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.